Literature DB >> 10510359

Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis.

A K Johnsen1, D J Templeton, M Sy, C V Harding.   

Abstract

Proteins involved in class I MHC (MHC-I) Ag processing, such as the TAP, are deficient in some human tumor cells. This suggests that antitumor responses by CD8 T cells provide selection pressure to favor outgrowth of cells with defective processing of tumor Ags. Nonetheless, this evidence is only correlative, and controlled in vivo experiments have been lacking to demonstrate that TAP deficiency promotes survival of tumor cells. To explore the role of Ag processing defects in tumor progression, matched panels of TAP1-positive and TAP1-negative tumor cell lines were generated from a parental transformed murine fibroblast line. Inoculation of C57BL/6 mice with TAP1-negative cells produced large and persistent tumors. In contrast, TAP1-positive cells did not generate lasting tumors, although small tumors were detected transiently and regressed spontaneously. Both TAP1-positive and TAP1-negative cells produced tumors in athymic mice, confirming that TAP-dependent differences in tumorigenicity were due to T cell-dependent immune responses. Inoculation of C57BL/6 mice with mixtures of TAP1-positive and TAP1-negative cells produced tumors composed exclusively of TAP1-negative cells, indicating in vivo selection for cells with TAP deficiency. Thus, loss of TAP function allows some tumor cells to avoid T cell-dependent elimination, resulting in selection for tumor cells with deficient Ag processing.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10510359

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

Review 1.  VEGF as a mediator of tumor-associated immunodeficiency.

Authors:  J E Ohm; D P Carbone
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 2.  Are BiTEs the "missing link" in cancer therapy?

Authors:  Carter M Suryadevara; Patrick C Gedeon; Luis Sanchez-Perez; Terence Verla; Christopher Alvarez-Breckenridge; Bryan D Choi; Peter E Fecci; John H Sampson
Journal:  Oncoimmunology       Date:  2015-04-30       Impact factor: 8.110

3.  Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability.

Authors:  Timothy T Spear; Timothy P Riley; Gretchen E Lyons; Glenda G Callender; Jeffrey J Roszkowski; Yuan Wang; Patricia E Simms; Gina M Scurti; Kendra C Foley; David C Murray; Lance M Hellman; Rachel H McMahan; Makio Iwashima; Elizabeth Garrett-Mayer; Hugo R Rosen; Brian M Baker; Michael I Nishimura
Journal:  J Leukoc Biol       Date:  2016-02-26       Impact factor: 4.962

Review 4.  Metabolic mechanisms of tumor resistance to T cell effector function.

Authors:  Candace M Cham; Thomas F Gajewski
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 5.  Toward beta cell replacement for diabetes.

Authors:  Bjarki Johannesson; Lina Sui; Donald O Freytes; Remi J Creusot; Dieter Egli
Journal:  EMBO J       Date:  2015-03-01       Impact factor: 11.598

6.  Epigenetic control of the immune escape mechanisms in malignant carcinomas.

Authors:  A Francesca Setiadi; Muriel D David; Robyn P Seipp; Jennifer A Hartikainen; Rayshad Gopaul; Wilfred A Jefferies
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

7.  Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?

Authors:  Simone Kayser; Iris Watermann; Christine Rentzsch; Toni Weinschenk; Diethelm Wallwiener; Brigitte Gückel
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-26       Impact factor: 4.553

8.  C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.

Authors:  Scott S Tykodi; Nobuharu Fujii; Nathalie Vigneron; Sharon M Lu; Jeffrey K Mito; Maureen X Miranda; Jeffrey Chou; Lilien N Voong; John A Thompson; Brenda M Sandmaier; Peter Cresswell; Benoît Van den Eynde; Stanley R Riddell; Edus H Warren
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

9.  Transporter associated protein expression in uveal melanoma.

Authors:  S Krishnakumar; S A Lakshmi; D Abhyankar; J Biswas
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

10.  HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.

Authors:  Liz Y Han; Mavis S Fletcher; Diana L Urbauer; Peter Mueller; Charles N Landen; Aparna A Kamat; Yvonne G Lin; William M Merritt; Whitney A Spannuth; Michael T Deavers; Koen De Geest; David M Gershenson; Susan K Lutgendorf; Soldano Ferrone; Anil K Sood
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.